Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot, Safety and Feasibility Trial of Anti-Thymocyte Globulin (ATG), Low Dose Interleukin-2 (IL-2), Adalimumab and Exenatide in the Treatment of New-Onset Type 1 Diabetes

NCT02586831 is registered in ClinicalTrials.gov with Camillo Ricordi and Jay Skyler as lead sponsor.

NCT NCT02586831
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02586831 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot, Safety and Feasibility Trial of Anti-Thymocyte Globulin (ATG), Low Dose Interleukin-2 (IL-2), Adalimumab and Exenatide in the Treatment of New-Onset Type 1 Diabetes
Lead sponsor
Camillo Ricordi and Jay Skyler
Phase
Phase 1/2
Overall status
Withdrawn
Start date
June 1, 2024
Completion date
June 1, 2024
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune diseases, diabetes mellitus, diabetes mellitus, type 1, hypoglycemia